Literature DB >> 26289822

Alignment of site versus adjudication committee-based diagnosis with patient outcomes: Insights from the Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 trial.

Nariman Sepehrvand1, Yinggan Zheng1, Paul W Armstrong1, Robert Welsh2, Shaun G Goodman3, Wayne Tymchak2, Fadi Khadour4, Michael Chan5, Dale Weiss6, Justin A Ezekowitz7.   

Abstract

BACKGROUND: Adjudication by an adjudication committee in clinical trials plays an important role in the assessment of outcomes. Controversy exists regarding the utility of adjudication committee versus site-based assessments and their relationship to subsequent clinical events.
METHODS: This study is a secondary analysis of the Providing Rapid Out of Hospital Acute Cardiovascular Treatment-3 trial, which randomized patients with chest pain or shortness of breath for biomarker testing in the ambulance. The emergency department physician diagnosis at the time of emergency department disposition was compared with an adjudicated diagnosis assigned by an adjudication committee. The level of agreement between emergency department and adjudication committee diagnosis was evaluated using kappa coefficient and compared to clinical outcomes (30-day re-hospitalization, 30-day and 1-year mortality).
RESULTS: Of the 477 patients, 49.3% were male with a median age of 70 years; hospital admission rate was 31.2%. The emergency department physicians and the adjudication committee disagreed in 55 cases (11.5%) with a kappa of 0.71 (95% confidence interval: 0.64, 0.78). The 30-day re-hospitalization, 30-day mortality, and 1-year mortality were 22%, 1.9%, and 9.4%, respectively. Although there were similar rates of re-hospitalization irrespective of adjudication, in cases of disagreement compared to agreement between adjudication committee and emergency department diagnosis, there was a higher 30-day (7.3% vs 1.2%, p = 0.002) and 1-year mortality (27.3% vs 7.1%, p < 0.001).
CONCLUSION: Despite substantial agreement between the diagnosis of emergency department physicians and adjudication committee, in the subgroup of patients where there was disagreement, there was significantly worse short-term and long-term mortality.
© The Author(s) 2015.

Entities:  

Keywords:  PROACT-3; adjudication; agreement; emergency department

Mesh:

Year:  2015        PMID: 26289822     DOI: 10.1177/1740774515601437

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  5 in total

1.  Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical Trials.

Authors:  Yiming Chen; John Lawrence; H M James Hung; Norman Stockbridge
Journal:  Ther Innov Regul Sci       Date:  2020-09-01       Impact factor: 1.778

2.  Providing Rapid Out of Hospital Acute Cardiovascular Treatment 4 (PROACT-4).

Authors:  Justin A Ezekowitz; Robert C Welsh; Dale Weiss; Michael Chan; William Keeble; Fadi Khadour; Sanjay Sharma; Wayne Tymchak; Sunil Sookram; Neil Brass; Darren Knapp; Thomas L Koshy; Yinggan Zheng; Paul W Armstrong
Journal:  J Am Heart Assoc       Date:  2015-12-01       Impact factor: 5.501

3.  Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events.

Authors:  Alexander C Fanaroff; Ghazala Haque; Betsy Thomas; Allegra E Stone; Lynn M Perkins; Matthew Wilson; W Schuyler Jones; Chiara Melloni; Kenneth W Mahaffey; Karen P Alexander; Renato D Lopes
Journal:  Trials       Date:  2020-04-09       Impact factor: 2.279

Review 4.  Central masked adjudication of stroke diagnosis at trial entry offered no advantage over diagnosis by local clinicians: Secondary analysis and simulation.

Authors:  Peter J Godolphin; Trish Hepburn; Nikola Sprigg; Liz Walker; Eivind Berge; Ronan Collins; John Gommans; George Ntaios; Stuart Pocock; Kameshwar Prasad; Joanna M Wardlaw; Philip M Bath; Alan A Montgomery
Journal:  Contemp Clin Trials Commun       Date:  2018-11-10

5.  Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis.

Authors:  Mary Farrant; J Donald Easton; Eric E Adelman; Brett L Cucchiara; William G Barsan; Holly J Tillman; Jordan J Elm; Anthony S Kim; Anne S Lindblad; Yuko Y Palesch; Wenle Zhao; Keith Pauls; Kyle B Walsh; Joan Martí-Fàbregas; Richard A Bernstein; S Claiborne Johnston
Journal:  JAMA Netw Open       Date:  2019-09-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.